Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
32134 | 112 | 23.0 | 28% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
124 | 23152 | HEPATITIS B VIRUS//CHRONIC HEPATITIS B//HEPATITIS B |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | IMMUNOLOGICAL AGENTS | Author keyword | 1 | 50% | 1% | 1 |
2 | INT MED PROGRAMME | Address | 1 | 50% | 1% | 1 |
3 | CLINICAL PREDICTIONS | Author keyword | 0 | 17% | 1% | 1 |
4 | MIR146A | Author keyword | 0 | 17% | 1% | 1 |
5 | KLINIKUM CHARLOTTENBURG POLIKLIN | Address | 0 | 100% | 1% | 1 |
6 | MTOR PATHWAYS | Author keyword | 0 | 100% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | IMMUNOLOGICAL AGENTS | 1 | 50% | 1% | 1 | Search IMMUNOLOGICAL+AGENTS | Search IMMUNOLOGICAL+AGENTS |
2 | CLINICAL PREDICTIONS | 0 | 17% | 1% | 1 | Search CLINICAL+PREDICTIONS | Search CLINICAL+PREDICTIONS |
3 | MIR146A | 0 | 17% | 1% | 1 | Search MIR146A | Search MIR146A |
4 | MTOR PATHWAYS | 0 | 100% | 1% | 1 | Search MTOR+PATHWAYS | Search MTOR+PATHWAYS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | STATES BLUETONGUE VIRUSES | 0 | 100% | 1% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
INDICATIONS FOR THE TREATMENT OF FULMINANT HEPATIC-FAILURE BY BABOON LIVER HEMOPERFUSION | 1983 | 1 | 5 | 60% |
VIRAL-HEPATITIS - A REVIEW | 1982 | 2 | 5 | 40% |
Statistical methods in cancer research | 2001 | 4 | 77 | 3% |
THE DIAGNOSTIC-SIGNIFICANCE OF ENZYMORRHEA | 1984 | 0 | 4 | 25% |
ENZYMES IN THE SMALL-INTESTINE | 1986 | 0 | 30 | 7% |
VIRAL-INFECTIONS DURING PREGNANCY | 1981 | 0 | 7 | 29% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | INT MED PROGRAMME | 1 | 50% | 0.9% | 1 |
2 | KLINIKUM CHARLOTTENBURG POLIKLIN | 0 | 100% | 0.9% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000125946 | ABT HERZ THORAX GEFAS IRURG ANASTHESIE INTENS//PAUL W PRUYSER//ABT ETHIK GE ICHTE MED |
2 | 0.0000125514 | CHLORMEZANONE//BLOOD CHEMILUMINESCENCE//2 ARYL 3 METHYLIDENETETRAHYDROFURANS |
3 | 0.0000124962 | IGM ANTI HBC//ANTI HBC IGM//HBVDNA |
4 | 0.0000081508 | HEPATITIS B VACCINE//HEPATITIS B//HEPATITIS B VACCINATION |
5 | 0.0000076761 | K M AND V MAX//PERFUSED MOUSE LIVER//N DESMETHYLDIAZEPAM |
6 | 0.0000067641 | EGG YOLK ANTIBODIES//ACTINOMYCIN C//HUMAN LIVER TISSUE |
7 | 0.0000063392 | HEPATITIS DELTA VIRUS//HEPATITIS D VIRUS//HDV RNA |
8 | 0.0000057234 | ORAL PHARMACOL THER EUT//PHARMACEUT SCI BIOPHARMACEUT MIZUHO KU//31 TANABE DORIMIZUHO KU |
9 | 0.0000056601 | NETHERLANDS ALTERNAT ANIM USE//TOXIN BINDING INHIBITION TEST//STEARYL TYROSINE |
10 | 0.0000052398 | ANTERIOR FONTANEL//ABT GASTROENTEROL INFEKTIOL HEPATOL//NORMATIVE MEASUREMENTS |